Fracture risks of antidepressants

References

• Videbech P, Sparle Christensen K, Buchholtz Hansen PE. Antidepressiva. In: Medicin.dk 2007. Pedersen C, Bjerrum L, Dalhoff KP, Damkier P, Friis H, Hendel J (Eds). Infomatum A/S, Copenhagen, Denmark, 373–386 (2007).
   Google Scholar
• Eskandari F, Martinez PE, Torvik S et al. Low bone mass in premenopausal women with depression. Arch. Intern. Med.167, 2329–2336 (2007).
   PubMedGoogle Scholar
• Robbins J, Hirsch C, Whitmer R, Cauley J, Harris T. The association of bone mineral density and depression in an older population. J. Am. Geriatr. Soc.49, 732–736 (2001).
   PubMed Web of Science ®Google Scholar
• Michelson D, Stratakis C, Hill L et al. Bone mineral density in women with depression. N. Engl. J. Med.335, 1176–1181 (1996).
   PubMed Web of Science ®Google Scholar
• Schweiger U, Weber B, Deuschle M, Heuser I. Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am. J. Psychiatry157, 118–120 (2000).
   PubMedGoogle Scholar
• Whooley MA, Kip KE, Cauley JA, Ensrud KE, Nevitt MC, Browner WS. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med159, 484–490 (1999).
   PubMedGoogle Scholar
• Reginster JY, Deroisy R, Paul I, Hansenne M, Ansseau M. Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas33, 133–137 (1999).
   PubMedGoogle Scholar
• Spangler L, Scholes D, Brunner RL et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J. Gen. Intern. Med.23, 567–574 (2008).
   PubMedGoogle Scholar
• Pollock BG. Adverse reactions of antidepressants in elderly patients. J. Clin. Psychiatry60(Suppl. 20), 4–8 (1999).
   PubMedGoogle Scholar
• Christensen P, Thomsen HY, Pedersen OL, Gram LF, Kragh-Sorensen P. Orthostatic side effects of clomipramine and citalopram during treatment for depression. Psychopharmacology (Berl.)86, 383–385 (1985).
   PubMedGoogle Scholar
• Rodriguez dlT, Dreher J, Malevany I et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug Monit.23, 435–440 (2001).
   PubMedGoogle Scholar
• Bliziotes M, Gunness M, Eshleman A, Wiren K. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J. Musculoskelet. Neuronal Interact.2, 291–295 (2002).
   PubMedGoogle Scholar
• Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology146, 685–693 (2005).
   PubMed Web of Science ®Google Scholar
• Haney EM, Chan BKS, Diem SJ et al; for the Osteoporotic Fractures in Men Study Group. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Int. Med.167, 1246–1251 (2007).
   PubMed Web of Science ®Google Scholar
• Richards JB, Papaioannou A, Adachi JD et al.; for the Canadian Multicentre Osteoporosis Study (CaMos) research group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Int. Med.167, 188–194 (2007).
   PubMed Web of Science ®Google Scholar
• Diem SJ, Blackwell TL, Stone KL et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch. Int. Med.167, 1240–1245 (2007).
   PubMed Web of Science ®Google Scholar
• Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int. Clin. Psychopharmacol.23, 84–87 (2008).
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Wang PS. Association between SSRI use and hip fractures and the effect of residual confounding bias in claims studies. J. Clin. Psychopharmacol.24, 632–638 (2004).
   PubMedGoogle Scholar
• Ensrud KE, Blackwell T, Mangione CM et al. Central nervous system active medications and risk for fractures in older women. Arch. Intern. Med.163, 949–957 (2003).
   PubMedGoogle Scholar
• Mussolino ME. Depression and hip fracture risk: the NHANES I epidemiologic follow-up study. Public Health Rep.120, 71–75 (2005).
   PubMedGoogle Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporosis Int.17, 807–816 (2006).
   PubMed Web of Science ®Google Scholar
• Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am. J. Epidemiol.158, 77–84 (2003).
   PubMed Web of Science ®Google Scholar
• Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet351, 1303–1307 (1998).
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif. Tissue Int.82, 92–101 (2008).
   PubMed Web of Science ®Google Scholar
• Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J. Clin. Psychopharmacol.28, 411–417 (2008).
   PubMed Web of Science ®Google Scholar
• Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD. Fracture risk from psychotropic medications: a population-based analysis. J. Clin. Psychopharmacol.28, 384–394 (2008).
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ312, 1254–1259 (1996).
   PubMed Web of Science ®Google Scholar